Dehydration Clinical Trial
Official title:
A Randomized, Placebo Controlled, Semi-Blind, Crossover Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Adults
The electrolyte test products are composed of powder and provided in individual stick packs with 5 vitamins including Vitamins B3, B5, B6, B12 and Vitamin C. The products are gluten-, soy-, and dairy-free, and provide electrolytes at concentrations well below the daily value (DV). The DV tells us how much a particular nutrient in a serving of a food product contributes to a daily diet, based on a standard 2000 calorie diet. Despite what the name suggests, this product is taken orally, not intravenously. These packets contain a small percentage of the needed total daily electrolytes but adequate amounts to replace lost electrolytes as a result of physical activity. The products will be consumed following a 90-minute bout of cycling exercise at a moderate intensity of 70-80% max heart rate, at 30-32°C (86-89°F) and 50 ± 5% relative humidity. This same exercise duration and room temperature has been used in a recent study, which also utilized the same body temperature monitoring device as proposed in the present study. The purpose of the exercise bout is to simulate what many individuals are exposed to when exercising in the heat and to moderately dehydrate subjects, as would be the case during a moderate run or cycling event in exercise-trained individuals. Subjects will report to the lab on three separate occasions to consume one of the 3 drinks (hydration multiplier, sugar-free hydration matrix, or water), in random order. The drinks will be consumed during the post-exercise period (30 minutes following the completion of exercise).
Status | Recruiting |
Enrollment | 25 |
Est. completion date | May 30, 2024 |
Est. primary completion date | May 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 49 Years |
Eligibility | Inclusion Criteria: - Body mass index (BMI) between 17.0-29.9 kg/m2 (not obese) - Resting heart rate less than 90 beats per minute; although, if less than 40 beats per minute subject must get clearance from a medical professional - Not hypertensive (Systolic <140 mmHg and Diastolic <90 mmHg) - Have not had in the 3 months prior to screening or planning to have a major surgery during study period - Physically capable and willing to ingest the assigned amount of fluid while cycling and at rest for visits 3, 4, and 5 - Must be moderately trained; engage in moderate intensity, intermittent, or steady-state exercise at least 3 days per week for at least one hour at a time. - Willing to maintain the same level of physical activity throughout the study period, except during the 24 hour period prior to each study visit. - Achieve a peak maximal oxygen consumption at screening that is at least 60% of their age and gender matched normative value per American College of Sports Medicine recommendations. - Capable of completing 90 minutes of self-paced stationary cycling (~70-80% max heart rate) in a heated environmental chamber (~30-32°C (86-89°F) with ~50% RH). - Can drink a minimum of 2.0 L fluid (if female) or 2.5 L fluid (if male) the day prior to test visits - For visits 3-5, subjects must have a urine specific gravity less than 1.020. - For visit 3-5, subject must not have exercised within 24 hours of visit - Consume no more than two standard alcoholic drinks per day on a regular basis and during study period. - Maintain diet, exercise, BMI, medication, and dietary supplements throughout study period as changes may alter hydration and electrolyte levels and result in changes to outcome measures. Exclusion Criteria: - If female, lactating, pregnant or planning to become pregnant during the study. - Have a known sensitivity or allergy to any of the study products - Have a history of diabetes - Have a history of known cardiovascular disease - Have a history of a diagnosis of celiac disease, chronic pancreatitis, steatorrhea, unstable thyroid disease, immune disorder (i.e., HIV/AIDS), cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit). - Have an active or uncontrolled diseases or conditions - Have had a current or previous Corona virus disease 2019 diagnosis in the three months prior to screening. - Have any medical conditions that may impact ability to exercise or ability to ingest prescribed fluid volume as determined by the study nurse, including infection or illness - Weighing less than 80 lbs at any visit; although very unlikely, we need to maintain this cut off, as too low a body mass is unhealthy. - Has taken within 30 days or within seven half-lives (whichever is longer) of first test visit: selective serotonin uptake inhibitors (SSRI), Apremilast, caffeine-containing drugs, Corticosteroids (systemic use), Decongestants, Diuretics, Laxatives, Muscle relaxants, Opioid painkillers, Statins, Oral antibiotics - Has taken within 30 days of first test visit: Calcium, Dandelion, Lithium orotate, Potassium citrate, Watercress, Inhalables smokables, or the like cigarettes, vaporizers, water pipes, or cannabis - Has taken within 24 hours prior to test visit: Alcohol, Caffeine (including coffee, tea, energy drinks, etc. prohibited in the 12hrs prior to each dose of the study product), Laxatives, Diuretics, or Sports drinks (electrolyte drinks) - received or use test product(s) in another research study in the 28 days prior to baseline visit (Familiarization, Visit/Visit 2), or longer if the previous test product is deemed by the investigator to have lasting effects that might influence the eligibility criteria or outcomes of the current study. - have any other active or unstable medical conditions or use medications, supplements, or therapies that, in the opinion of the investigator, may adversely affect the participant's ability to complete the study or its measures or pose a significant risk to the participant. |
Country | Name | City | State |
---|---|---|---|
United States | Center for Nutraceutical and Dietary Supplement Research | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
University of Memphis |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Body weight | body weight will be measured using a digital scale | baseline (prior to cycling) | |
Primary | Body weight | body weight will be measured using a digital scale | 0 minutes after 90-minute cycle bout | |
Primary | Body weight | body weight will be measured using a digital scale | 30 minutes after cycling | |
Primary | Body weight | body weight will be measured using a digital scale | 4 hours and 30 minutes after cycling | |
Primary | Urine Volume | urine will be collected in a tray and then weighed on a digital scale | baseline (prior to cycling) | |
Primary | Urine Volume | urine will be collected in a tray and then weighed on a digital scale | 0 minutes after cycling | |
Primary | Urine Volume | urine will be collected in a tray and then weighed on a digital scale | 30 minutes after cycling | |
Primary | Urine Volume | urine will be collected in a tray and then weighed on a digital scale | 1 hour 30 minutes after cycling (following rehydration period) | |
Primary | Urine Volume | urine will be collected in a tray and then weighed on a digital scale | 2 hours 30 minutes after cycling | |
Primary | Urine Volume | urine will be collected in a tray and then weighed on a digital scale | 3 hours 30 minutes after cycling | |
Primary | Urine Volume | urine will be collected in a tray and then weighed on a digital scale | 4 hours 30 minutes after cycling | |
Primary | Urine osmolality | Osmolality will be determined from a urine sample collected in a tray | baseline (prior to cycling) | |
Primary | Urine osmolality | Osmolality will be determined from a urine sample collected in a tray | 0 minutes after cycling | |
Primary | Urine osmolality | Osmolality will be determined from a urine sample collected in a tray | 30 minutes after cycling | |
Primary | Urine osmolality | Osmolality will be determined from a urine sample collected in a tray | 1 hour 30 minutes after cycling (following rehydration period) | |
Primary | Urine osmolality | Osmolality will be determined from a urine sample collected in a tray | 2 hour 30 minutes after cycling (following rehydration period) | |
Primary | Urine osmolality | Osmolality will be determined from a urine sample collected in a tray | 3 hour 30 minutes after cycling (following rehydration period) | |
Primary | Urine osmolality | Osmolality will be determined from a urine sample collected in a tray | 4 hour 30 minutes after cycling (following rehydration period) | |
Primary | Urine specific gravity | specific gravity will be determined using a refractometer from a urine sample collected | first morning urine (~2 hours before visit) | |
Primary | Urine specific gravity | specific gravity will be determined using a refractometer from a urine sample collected | baseline (before cycling) | |
Primary | Urine specific gravity | specific gravity will be determined using a refractometer from a urine sample collected | 0 minutes after cycling | |
Primary | Urine specific gravity | specific gravity will be determined using a refractometer from a urine sample collected | 30 minutes after cycling | |
Primary | Urine specific gravity | specific gravity will be determined using a refractometer from a urine sample collected | 1 hour 30 minutes after cycling (following rehydration period) | |
Primary | Urine specific gravity | specific gravity will be determined using a refractometer from a urine sample collected | 2 hour 30 minutes after cycling (following rehydration period) | |
Primary | Urine specific gravity | specific gravity will be determined using a refractometer from a urine sample collected | 3 hour 30 minutes after cycling (following rehydration period) | |
Primary | Urine specific gravity | specific gravity will be determined using a refractometer from a urine sample collected | 4 hour 30 minutes after cycling (following rehydration period) | |
Primary | Plasma Osmolality | Blood will be collected to determine plasma osmolality | baseline (before cycling) | |
Primary | Electrolyte levels | electrolyte levels will be measured in blood | baseline (before cycling) | |
Primary | Percent plasma volume | Percent plasma volume will be determined by measuring hematocrit and hemoglobin in blood. | baseline (before cycling) | |
Primary | Plasma Osmolality | Blood will be collected to determine plasma osmolality | 30 minutes post cycling | |
Primary | Electrolyte levels | electrolyte levels (Sodium, potassium, chloride, and carbon dioxide total) will be measured in blood (millimoles per liter) | 30 minutes post cycling | |
Primary | Percent plasma volume | Percent plasma volume will be determined by measuring hematocrit and hemoglobin in blood. | 30 minutes post cycling | |
Primary | Plasma Osmolality | Blood will be collected to determine plasma osmolality | 60 minutes post cycling | |
Primary | Electrolyte levels | electrolyte levels (Sodium, potassium, chloride, and carbon dioxide total) will be measured in blood (millimoles per liter) | 60 minutes post cycling | |
Primary | Percent plasma volume | Percent plasma volume will be determined by measuring hematocrit and hemoglobin in blood. | 60 minutes post cycling | |
Primary | Plasma Osmolality | Blood will be collected to determine plasma osmolality | 120 minutes post cycling | |
Primary | Electrolyte levels | electrolyte levels (Sodium, potassium, chloride, and carbon dioxide total) will be measured in blood (millimoles per liter) | 120 minutes post cycling | |
Primary | Percent plasma volume | Percent plasma volume will be determined by measuring hematocrit and hemoglobin in blood. | 120 minutes post cycling | |
Primary | Plasma Osmolality | Blood will be collected to determine plasma osmolality | 150 minutes post cycling | |
Primary | Electrolyte levels | electrolyte levels (Sodium, potassium, chloride, and carbon dioxide total) will be measured in blood (millimoles per liter) | 150 minutes post cycling | |
Primary | Percent plasma volume | Percent plasma volume will be determined by measuring hematocrit and hemoglobin in blood. | 150 minutes post cycling | |
Primary | Plasma Osmolality | Blood will be collected to determine plasma osmolality | 210 minutes post cycling | |
Primary | Electrolyte levels | electrolyte levels (Sodium, potassium, chloride, and carbon dioxide total) will be measured in blood (millimoles per liter) | 210 minutes post cycling | |
Primary | Percent plasma volume | Percent plasma volume will be determined by measuring hematocrit and hemoglobin in blood. | 210 minutes post cycling | |
Primary | Plasma Osmolality | Blood will be collected to determine plasma osmolality | 270 minutes post cycling | |
Primary | Electrolyte levels | electrolyte levels (Sodium, potassium, chloride, and carbon dioxide total) will be measured in blood (millimoles per liter) | 270 minutes post cycling | |
Primary | Percent plasma volume | Percent plasma volume will be determined by measuring hematocrit and hemoglobin in blood. | 270 minutes post cycling | |
Secondary | Body temperature | Body temperature will be monitored during cycling | Every 10 minutes during cycling | |
Secondary | Heart rate | Heart rate will be monitored during cycling | Every 10 minutes during cycling | |
Secondary | Rate of Perceived Exertion | Rate of Perceived Exertion using a Borg scale from 6 (easy) to 20 (maximal effort) will be reported during cycling | Every 10 minutes during cycling | |
Secondary | maximal oxygen consumption | maximal oxygen consumption will be determined via a cycling test | At screening | |
Secondary | Height | Height will be measured using a stadiometer | At screening | |
Secondary | Weight | Weight will be determined using a digital scale | At screening | |
Secondary | Waist/Hip ratio | Waist/Hip ratio will be determined by measuring each circumference with a tape measure | At screening | |
Secondary | Resting Diastolic Blood Pressure | Diastolic blood pressure will be measured after a 10 minute rest sitting using a digital machine | At screening | |
Secondary | Resting Systolic Blood Pressure | Systolic blood pressure will be measured after a 10 minute rest sitting using a digital machine | At screening | |
Secondary | Heart Rate | Heart Rate will be measured after a 10 minute rest sitting using a digital machine | At screening |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04079543 -
NPO and Patient Satisfaction in the Cath Lab
|
N/A | |
Completed |
NCT05111392 -
Hydration Dynamics and Influence of Beverage Composition
|
Phase 1/Phase 2 | |
Terminated |
NCT02486224 -
Metabolomic Analysis of the Impacts of Hydration Status on Exercise Performance
|
N/A | |
Recruiting |
NCT02249845 -
Comparing the Diagnostic Accuracy of Clinical Dehydration Scales Among Small Children
|
N/A | |
Completed |
NCT01285713 -
IV Glucose for Dehydration Treatment
|
Phase 2 | |
Withdrawn |
NCT00691275 -
Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration
|
N/A | |
Completed |
NCT00360204 -
Improving Health Outcomes for New Mothers and Babies
|
Phase 3 | |
Completed |
NCT00370968 -
Zinc-ORS in Severe and Complicated Acute Diarrhea
|
Phase 2/Phase 3 | |
Completed |
NCT04076995 -
INDIGO-2: The Effect of High Water Intake on Glucose Regulation in Low-drinkers
|
N/A | |
Recruiting |
NCT05768789 -
Buoy Electrolyte Study on Hydration Status of Active Men and Women
|
N/A | |
Not yet recruiting |
NCT05428228 -
Clinical Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults
|
N/A | |
Completed |
NCT04997031 -
Tap Water Intake and Perceptions in US Latinx Adults
|
||
Completed |
NCT04536324 -
The Absorption Rate of Subcutaneous Infused Fluid
|
||
Completed |
NCT02926989 -
Intravenous Fluids in Hospitalised Children
|
Phase 4 | |
Completed |
NCT04874584 -
Culturally Tailored Nurse Coaching Study for Cancer Symptom Management
|
N/A | |
Completed |
NCT02206581 -
Using Hydration Monitor to Detect Changes in the Hydration Status Athletes
|
N/A | |
Completed |
NCT02265575 -
Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration
|
Phase 2 | |
Completed |
NCT01893853 -
Fluid Balance During Exercise in the Heat With Water, Flavored Placebo, or a Carbohydrate-electrolyte Beverage Intake (The APEX Study)
|
N/A | |
Completed |
NCT01503996 -
Drinking Habits of Glaucoma Patients and Age Matched Controls
|
N/A | |
Completed |
NCT01268826 -
DESHYDRAT : Assessment of the Prevalence of Dehydration Among 9 to 11 Year-old Children
|
N/A |